Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. (Q44029872)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

amyotrophic lateral sclerosis

10 November 2019

main subject

0 references

author

Piotr Janik

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

I Niebroj-Dobosz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

H Kwieciński

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

Acta Neurologica Scandinavica

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

39-43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12067327%20AND%20SRC:MED&resulttype=core&format=json

Excitotoxic neuronal cell death in amyotrophic lateral sclerosis

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Glutamate, excitotoxicity and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Free amino acid levels in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

A disorder of biogenic amines in dihydropteridine reductase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Riluzole: a new agent for amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Management of amyotrophic lateral sclerosis with riluzole

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

High performance liquid chromatographic determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phthaldialdehyde

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Fluorescence reaction for amino acids

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Elevated levels of amino acids in the CSF of motor neuron disease patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021

Neuroprotective effects of riluzole in ALS CSF toxicity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.00206.X

7 January 2021